Literature DB >> 31156947

Oral etoposide in Merkel cell carcinoma.

Tatiana Betancor1, Maria Micaela Viña1, Sara Ramos1, Miguel Angel Cabrera2, Francisco Javier Merino1.   

Abstract

BACKGROUND: Merkel cell carcinoma (MCC) is a very infrequent and aggressive skin tumor with high recurrence and metastasis rates. MCC treatment is currently not well defined. CASE
PRESENTATION: We present the case of a 75-year-old woman who was diagnosed with MCC in 2010 and suffered a third relapse in 2012 which could not be treated surgically.
RESULTS: The patient began oral etoposide treatment reaching complete response after eight cycles and receiving a total of 11 cycles. As side effects, the patient suffered from neutropenia, candidiasis and mucositis, but after reducing the dosage to 50% it was well tolerated. DISCUSSION: Chemotherapy treatment in this setting is poorly defined. In this case, monotherapy treatment with oral etoposide was decided due to the patient's age and comorbidities, achieving a very positive outcome.

Entities:  

Keywords:  bibliographic research; chemotheraphy; etoposide; merkel cell carcinoma; skin carcinoma

Year:  2017        PMID: 31156947      PMCID: PMC6451579          DOI: 10.1136/ejhpharm-2016-001194

Source DB:  PubMed          Journal:  Eur J Hosp Pharm        ISSN: 2047-9956


  14 in total

Review 1.  Merkel cell carcinoma.

Authors:  J C Becker
Journal:  Ann Oncol       Date:  2010-10       Impact factor: 32.976

2.  Merkel cell carcinoma adjuvant therapy: current data support radiation but not chemotherapy.

Authors:  Kelly M Garneski; Paul Nghiem
Journal:  J Am Acad Dermatol       Date:  2007-05-07       Impact factor: 11.527

3.  Oral etoposide for Merkel cell carcinoma in patients previously treated with intravenous etoposide.

Authors:  E Fenig; B Brenner; E Njuguna; A Katz; J Schachter; A Sulkes
Journal:  Am J Clin Oncol       Date:  2000-02       Impact factor: 2.339

4.  Expression of TdT in Merkel cell carcinoma and small cell lung carcinoma.

Authors:  Michael Sidiropoulos; Wedad Hanna; Simon J Raphael; Zeina Ghorab
Journal:  Am J Clin Pathol       Date:  2011-06       Impact factor: 2.493

5.  Adjuvant local irradiation for Merkel cell carcinoma.

Authors:  Kevan G Lewis; Martin A Weinstock; Amy L Weaver; Clark C Otley
Journal:  Arch Dermatol       Date:  2006-06

6.  Merkel cell carcinoma: prognosis and treatment of patients from a single institution.

Authors:  Peter J Allen; Wilbur B Bowne; David P Jaques; Murray F Brennan; Klaus Busam; Daniel G Coit
Journal:  J Clin Oncol       Date:  2005-04-01       Impact factor: 44.544

7.  Does chemotherapy improve survival in high-risk stage I and II Merkel cell carcinoma of the skin?

Authors:  Michael G Poulsen; Danny Rischin; Ian Porter; Euan Walpole; Jennifer Harvey; Chris Hamilton; Jacqui Keller; Lee Tripcony
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-08-25       Impact factor: 7.038

Review 8.  Friedrich Sigmund Merkel and his "Merkel cell", morphology, development, and physiology: review and new results.

Authors:  Zdenek Halata; Milos Grim; Klaus I Bauman
Journal:  Anat Rec A Discov Mol Cell Evol Biol       Date:  2003-03

9.  High-risk Merkel cell carcinoma of the skin treated with synchronous carboplatin/etoposide and radiation: a Trans-Tasman Radiation Oncology Group Study--TROG 96:07.

Authors:  Michael Poulsen; Danny Rischin; Euan Walpole; Jennifer Harvey; John Mackintosh; Jill Ainslie; Chris Hamilton; Jacqui Keller; Lee Tripcony
Journal:  J Clin Oncol       Date:  2003-12-01       Impact factor: 44.544

10.  Merkel cell carcinoma.

Authors:  Stanley J Miller; Murad Alam; James Andersen; Daniel Berg; Christopher K Bichakjian; Glen Bowen; Richard T Cheney; L Frank Glass; Roy C Grekin; Dennis E Hallahan; Anne Kessinger; Nancy Y Lee; Nanette Liegeois; Daniel D Lydiatt; Jeff Michalski; William H Morrison; Kishwer S Nehal; Kelly C Nelson; Paul Nghiem; Thomas Olencki; Allan R Oseroff; Clifford S Perlis; E William Rosenberg; Ashok R Shaha; Marshall M Urist; Linda C Wang
Journal:  J Natl Compr Canc Netw       Date:  2009-03       Impact factor: 12.693

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.